Therapy-Driven Molecular Evolution of Bladder Cancer: Roles of Cellular Plasticity and Tumor Microenvironment
International Journal of Molecular Sciences · 2026
DOI: 10.3390/ijms27125152 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Seung-Woo Baek und 3 weiteren Autor:innen. Beteiligte Einrichtung: Genomic Medicine Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon 34141, Republic of Korea. Hauptthemen laut MEDLINE: Tumor Microenvironment, Urinary Bladder Neoplasms, Drug Resistance, Neoplasm, Cell Plasticity. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 102 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea, Korea Research Institute of Bioscience and Biotechnology, Ministry of Education.
Abstract (Originalsprache)
Drug resistance remains a significant barrier to achieving durable treatment responses. Traditionally, resistance has been attributed to genetic alterations and clonal selection. However, accumulating evidence suggests that early adaptation to therapy is often mediated by non-genetic state transitions. In this review, we propose a conceptual framework in which resistance emerges through therapy-driven molecular evolution in bladder cancer, characterized by three interconnected axes: non-genetic plasticity, metabolic reorganization, and tumor microenvironment remodeling. Using the Gemcitabine-Resistant Cell (GRC) model as a temporal reference system, we describe a stepwise transition from drug-sensitive states dominated by proliferation to survival-optimized resistant states through a growth–survival trade-off. Early adaptive phases are marked by the attenuation of cell-cycle and glycolytic programs, increased epigenetic flexibility, and metabolic rewiring involving mitochondrial and lipid-associated pathways. Later phases involve the reinforcement of resistance through extracellular matrix remodeling, developmental and stress-response signaling, and immunometabolic interactions within the tumor microenvironment, including adenosine- and lipid-associated mediators. Projecting the GRC score onto a clinical bladder cancer cohort further suggests that these evolutionary patterns may also be reflected in patient tumors. Overall, this framework supports a temporally structured view of chemoresistance and highlights opportunities to therapeutically target transitional adaptive states before resistance becomes stabilized.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Genomic Medicine Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon 34141, Republic of Korea.
- Department of Biomedical Sciences, Dong-A University, Busan 49315, Republic of Korea.
- Department of Health Sciences, The Graduated of Dong-A University, Busan 49315, Republic of Korea.
- Department of Bioscience, University of Science and Technology, Daejeon 34141, Republic of Korea.
ORCID-Profile: Seung-Woo Baek, Seon-Kyu Kim
Förderung
- National Research Foundation of Korea
- Korea Research Institute of Bioscience and Biotechnology
- Ministry of Education
Zitieren
APA
Baek, S. W., Yoon, S. Y., Kim, S. K., & Leem, S. H. (2026). Therapy-Driven Molecular Evolution of Bladder Cancer: Roles of Cellular Plasticity and Tumor Microenvironment. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27125152
Vancouver
Baek SW, Yoon SY, Kim SK, Leem SH. Therapy-Driven Molecular Evolution of Bladder Cancer: Roles of Cellular Plasticity and Tumor Microenvironment. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27125152
BibTeX
@article{Baek2026,
author = {Baek, Seung-Woo and Yoon, Seo-Young and Kim, Seon-Kyu and Leem, Sun-Hee},
title = {Therapy-Driven Molecular Evolution of Bladder Cancer: Roles of Cellular Plasticity and Tumor Microenvironment},
journal = {International Journal of Molecular Sciences},
year = {2026},
doi = {10.3390/ijms27125152}
}
EUVIMED